E2F-1 Antibody (YA5305)

Cat. No.: HY-P85613: Data Sheet User Guide for Antibodies
FAQs
Technical Support

E2F-1 Antibody (YA5305) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to E2F-1.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

E2F-1 Antibody (YA5305) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to E2F-1.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Observed band size: 60 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Rat

SwissProt ID

Q01094

Gene ID

1869 [NCBI]

Immunogen

Purified recombinant human E2F-1 protein fragments expressed in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:100
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-200

Purity	affinity chromatography.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication (PubMed:10675335, PubMed:12717439, PubMed:17050006, PubMed:17704056, PubMed:18625225, PubMed:28992046). The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase (PubMed:10675335, PubMed:12717439, PubMed:17704056). E2F1 binds preferentially RB1 in a cell-cycle dependent manner (PubMed:10675335, PubMed:12717439, PubMed:17704056). It can mediate both cell proliferation and TP53/p53-dependent apoptosis (PubMed:8170954). Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed:20176812). Directly activates transcription of PEG10 (PubMed:17050006, PubMed:18625225, PubMed:28992046). Positively regulates transcription of RRP1B (PubMed:20040599)

Subcellular Localization：Nucleus

Subunit：Component of the DRTF1/E2F transcription factor complex. Forms heterodimers with DP family members. The E2F1 complex binds specifically hypophosphorylated RB1, the interaction represses E2F1-driven transcription (PubMed:8336704). During the cell cycle, RB1 becomes phosphorylated in mid-to-late G1 phase, detaches from the DRTF1/E2F complex, rendering E2F transcriptionally active. Viral oncoproteins, notably E1A, T-antigen and HPV E7, are capable of sequestering RB1, thus releasing the active complex. Interacts with TRRAP, which probably mediates its interaction with histone acetyltransferase complexes, leading to transcription activation. Binds TOPBP1 and EAPP. Interacts with ARID3A. Interacts with TRIM28; the interaction inhibits E2F1 acetylation through recruiting HDAC1 and represses its transcriptional activity. Interaction with KAT2B; the interaction acetylates E2F1 enhancing its DNA-binding and transcriptional activity. Interacts with BIRC2/c-IAP1 (via BIR domains). The complex TFDP1:E2F1 interacts with CEBPA; the interaction prevents CEBPA binding to target genes promoters and represses its transcriptional activity (PubMed:20176812). Interacts with RRP1B (PubMed:20040599). Interacts with HCFC1 (PubMed:23629655). Interacts with KMT2E; the interaction is probably indirect and is mediated via HCFC1 (PubMed:23629655). Interacts with DCAF5 and L3MBTL3; the interaction requires methylation at Lys-185 and is necessary to target E2F1 for ubiquitination by the CRL4-DCAF5 E3 ubiquitin ligase complex (PubMed:29691401)

Synonyms

Dmel\CG6376; Dmel_CG6376; drosE2F1; E; Sev-CycE; 3A; E; var; 3-93E; E2-promoter binding facto; E2F 1; E2F transcription factor 1; E2F-1; E2f-PA; E2f-PB; E2f-PC; E2F1; E2f1 E2F transcription factor 1; E2F1_HUMAN; Evar; 3; 164; KIAA4009; l; 3; 07172; l; 3; j3B1; l; 3; j3C2; l; 3; rM729; mKIAA4009; OTTHUMP00000030661; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma-associated protein 1; Retinoblastoma-binding protein 3; Transcription factor E2F1.

Documentation

User Guide for Antibodies (1077 KB)